NCT07030348
Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study
At risk: Primary completion moved 5 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 12 words
- Primary completion pushed from Dec 31, 2026 to May 31, 2027
- Study completion pushed from Dec 31, 2026 to Dec 31, 2027
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Identification of Biomarkers for Early Pancreatic Cancer Detection
Timeframe: Up to 1 year from baseline
Secondary (1)
External Validation Using U.S. Samples
Arms and interventions
Pancreatic Cancer Group (DP)
Participants with a biopsy with proven stage I-IV pancreatic ductal adenocarcinoma (PDAC), or with suspected pancreatic cancer on imaging and scheduled for an endoscopic ultrasound-guided pancreatic biopsy.
Non-Pancreatic Cancer Group (DC)
Participants with pancreatic cystic tumors or with acute or chronic pancreatitis, or with no evidence of a pancreatic disease
Sites
3 sites in 2 countries
United States 2, South Korea 1